Anil Chandraker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2264952/publications.pdf

Version: 2024-02-01

134 7,921 papers citations

71102 51608 41 h-index

> 9894 citing authors

86

g-index

142 all docs 142 docs citations 142 times ranked

#	Article	IF	CITATIONS
1	Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature Medicine, 2007, 13, 952-961.	30.7	1,862
2	EFFECTS OF EXPLOSIVE BRAIN DEATH ON CYTOKINE ACTIVATION OF PERIPHERAL ORGANS IN THE RAT1. Transplantation, 1998, 65, 1533-1542.	1.0	373
3	The promise of organ and tissue preservation to transform medicine. Nature Biotechnology, 2017, 35, 530-542.	17.5	371
4	Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance. Journal of Experimental Medicine, 1998, 187, 2037-2044.	8 . 5	328
5	A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1. Transplantation, 2003, 76, 798-802.	1.0	223
6	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	4.7	205
7	The APOL1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5-Year Allograft Survival. American Journal of Transplantation, 2012, 12, 1924-1928.	4.7	161
8	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.8	159
9	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Journal of Clinical Investigation, 2000, 105, 643-651.	8.2	158
10	Cutting Edge: Recipient MHC Class II Expression Is Required to Achieve Long-Term Survival of Murine Cardiac Allografts After Costimulatory Blockade. Journal of Immunology, 2001, 167, 5522-5526.	0.8	123
11	Pharmacoepidemiology of Anemia in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1347-1352.	6.1	123
12	Deleterious Effect of CTLA4-Ig on a Treg-Dependent Transplant Model. American Journal of Transplantation, 2012, 12, 846-855.	4.7	123
13	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. Journal of Immunology, 2011, 187, 1113-1119.	0.8	115
14	Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. Journal of the American Society of Nephrology: JASN, 2022, 33, 238-252.	6.1	112
15	ANTI-CD154 OR CTLA4Ig OBVIATES THE NEED FOR THYMIC IRRADIATION IN A NON-MYELOABLATIVE CONDITIONING REGIMEN FOR THE INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AND TOLERANCE1. Transplantation, 1999, 68, 1348-1355.	1.0	108
16	Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant Rejection. ACS Nano, 2017, 11, 11041-11046.	14.6	106
17	CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury: Rapid Communication. Kidney International, 1997, 52, 1678-1684.	5.2	98
18	INHIBITION OF CD26/DIPEPTIDYL PEPTIDASE IV ACTIVITY IN VIVO PROLONGS CARDIAC ALLOGRAFT SURVIVAL IN RAT RECIPIENTS1,2. Transplantation, 1997, 63, 1495-1500.	1.0	97

#	Article	IF	CITATIONS
19	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. American Journal of Transplantation, 2019, 19, 2876-2888.	4.7	95
20	Evaluation of Fluoroquinolones for the Prevention of BK Viremia after Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1298-1304.	4.5	94
21	Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy. Circulation, 2008, 117, 660-669.	1.6	89
22	Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. Journal of Clinical Investigation, 2001, 107, 909-916.	8.2	89
23	The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo. Journal of Immunology, 2003, 170, 2949-2955.	0.8	86
24	Efficacy of Levofloxacin in the Treatment of BK Viremia. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 583-589.	4.5	79
25	Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2016, 11, e0158431.	2.5	79
26	Hepatocyte Growth Factor Prevents the Development of Chronic Allograft Nephropathy in Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 1280-1292.	6.1	72
27	TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. International Journal of Oncology, 2015, 47, 857-866.	3.3	69
28	CD28-B7 T CELL COSTIMULATORY BLOCKADE BY CTLA4lg IN THE RAT RENAL ALLOGRAFT MODEL1,2. Transplantation, 1996, 62, 1942-1945.	1.0	66
29	A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrology Dialysis Transplantation, 2006, 21, 3559-3566.	0.7	64
30	CD28-B7-Mediated T Cell Costimulation in Chronic Cardiac Allograft Rejection. American Journal of Pathology, 2001, 158, 977-986.	3.8	63
31	Mechanisms and Role of HLA and non-HLA Alloantibodies. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 404-414.	4.5	62
32	T-CELL COSTIMULATORY BLOCKADE IN EXPERIMENTAL CHRONIC CARDIAC ALLOGRAFT REJECTION. Transplantation, 1997, 63, 1053-1058.	1.0	56
33	Inhibition of Simian Virus 40 Large T Antigen Helicase Activity by Fluoroquinolones. Antiviral Therapy, 2007, 12, 1-6.	1.0	55
34	VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2013, 32, 120-128.	0.6	53
35	Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2005, 16, 255-260.	6.1	51
36	Regulatory T Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1760-1764.	4.5	46

#	Article	IF	Citations
37	Five-Year Follow-up after Face Transplantation. New England Journal of Medicine, 2019, 380, 2579-2581.	27.0	46
38	The Role of B/T Costimulatory Signals in the Immunopotentiating Activity of Neisserial Porin. Journal of Infectious Diseases, 1999, 180, 755-761.	4.0	45
39	Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. International Journal of Molecular Sciences, 2016, 17, 2060.	4.1	45
40	Bacterial Pathogens Induce Abscess Formation by CD4 + T-Cell Activation via the CD28–B7-2 Costimulatory Pathway. Infection and Immunity, 2000, 68, 6650-6655.	2,2	44
41	Long-Term Outcomes of Kidney Transplantation Across a Positive Complement-Dependent Cytotoxicity Crossmatch. Transplantation, 2014, 97, 1247-1252.	1.0	44
42	Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 994-1004.	6.1	44
43	MECHANISMS OF INDIRECT ALLORECOGNITION. Transplantation, 1998, 65, 876-883.	1.0	44
44	Salt Accelerates Allograft Rejection through Serum- and Glucocorticoid-Regulated Kinase-1–Dependent Inhibition of Regulatory T Cells. Journal of the American Society of Nephrology: JASN, 2015, 26, 2341-2347.	6.1	43
45	Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce. American Journal of Transplantation, 2019, 19, 1888-1895.	4.7	42
46	Indirect Allorecognition of Donor Class I and II Major Histocompatibility Complex Peptides Promotes the Development of Transplant Vasculopathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 2500-2506.	6.1	42
47	Animal Models of Chronic Allograft Injury: Contributions and Limitations to Understanding the Mechanism of Long-Term Graft Dysfunction. Transplantation, 2010, 90, 935-944.	1.0	41
48	Metabolomic Profiling in Individuals with a Failing Kidney Allograft. PLoS ONE, 2017, 12, e0169077.	2.5	39
49	Blockade of Notch Ligand Delta 1 Promotes Allograft Survival by Inhibiting Alloreactive Th1 Cells and Cytotoxic T Cell Generation. Journal of Immunology, 2011, 187, 4629-4638.	0.8	38
50	COMPARATIVE STUDIES OF SPECIFIC ACQUIRED SYSTEMIC TOLERANCE INDUCED BY INTRATHYMIC INOCULATION OF A SINGLE SYNTHETIC WISTAR-FURTH (RT1U) ALLO-MHC CLASS I (RT1.AU) PEPTIDE OR WAG (RT1U)-DERIVED CLASS I PEPTIDE1. Transplantation, 1998, 66, 1059-1066.	1.0	38
51	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	2.8	37
52	Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2000, 105, 1109-1116.	8.2	36
53	Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. Oncotarget, 2016, 7, 68749-68767.	1.8	36
54	Mechanisms of targeting cd28 by a signaling monoclonal antibody in acute and chronic allograft rejection1. Transplantation, 2002, 73, 1310-1317.	1.0	34

#	Article	IF	CITATIONS
55	Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney International, 2002, 62, 627-631.	5.2	33
56	Interaction Between ICOS-B7RP1 and B7-CD28 Costimulatory Pathways in Alloimmune Responses In Vivo. American Journal of Transplantation, 2003, 3, 390-395.	4.7	32
57	Derivation and Validation of a Cytokine-Based Assay to Screen for Acute Rejection in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1018-1025.	4.5	32
58	Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Transplant International, 2006, 19, 351-359.	1.6	31
59	Diagnostic techniques in the work-up of renal allograft dysfunction - an update. Current Opinion in Nephrology and Hypertension, 1999, 8, 723-728.	2.0	31
60	Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight, 2017, 2, .	5.0	31
61	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. Journal of Clinical Investigation, 2018, 128, 3490-3503.	8.2	31
62	Monocyte-Secreted Inflammatory Cytokines Are Associated With Transplant Glomerulopathy in Renal Allograft Recipients. Transplantation, 2011, 91, 552-559.	1.0	30
63	Atovaquone versus trimethoprim–sulfamethoxazole as <i><scp>P</scp>neumocystis jirovecii</i> pneumonia prophylaxis following renal transplantation. Clinical Transplantation, 2012, 26, E184-90.	1.6	30
64	Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. Journal of the American Society of Nephrology: JASN, 2015, 26, 3102-3113.	6.1	28
65	Follicular T cells mediate donor-specific antibody and rejection after solid organ transplantation. American Journal of Transplantation, 2021, 21, 1893-1901.	4.7	28
66	Paradoxical Functions of B7: CD28 Costimulation in a MHC Class II-Mismatched Cardiac Transplant Model. American Journal of Transplantation, 2009, 9, 2837-2844.	4.7	27
67	Chronic Allograft Nephropathy. Seminars in Nephrology, 2007, 27, 414-429.	1.6	26
68	In Vitro and in Vivo Immunomodulatory Effects of RDP1258, a Novel Synthetic Peptide. Journal of the American Society of Nephrology: JASN, 1999, 10, 1997-2005.	6.1	26
69	Upregulated Heat Shock Proteins After Hyperthermic Chemotherapy Point to Induced Cell Survival Mechanisms in Affected Tumor Cells From Peritoneal Carcinomatosis. Cancer Growth and Metastasis, 2017, 10, 117906441773055.	3.5	25
70	BK Viral Reactivation in Cardiac Transplant Patients: Evidence for a Double-hit Hypothesis. Journal of Heart and Lung Transplantation, 2006, 25, 814-819.	0.6	24
71	Glomerular Inflammation Correlates With Endothelial Injury and With IL-6 and IL- $1\hat{l}^2$ Secretion in the Peripheral Blood. Transplantation, 2014, 97, 1034-1042.	1.0	24
72	DISTINCT TOLERANCE PATHWAYS IN SENSITIZED ALLOGRAFT RECIPIENTS AFTER SELECTIVE BLOCKADE OF ACTIVATION SIGNAL 1 OR SIGNAL 21. Transplantation, 1999, 68, 288-293.	1.0	24

#	Article	IF	CITATIONS
73	Facial Transplantation and Immunosuppressed Patients: A New Frontier in Reconstructive Surgery. Transplantation, 2008, 85, 1693-1697.	1.0	23
74	Jagged2â€signaling promotes <scp>IL</scp> â€6â€dependent transplant rejection. European Journal of Immunology, 2013, 43, 1449-1458.	2.9	23
75	A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection1. Transplantation, 2002, 73, 1736-1742.	1.0	21
76	Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney International, 2011, 79, 1005-1012.	5.2	21
77	Full facial retransplantation in a female patient—Technical, immunologic, and clinical considerations. American Journal of Transplantation, 2021, 21, 3472-3480.	4.7	21
78	Longitudinal immunological characterization of the first presensitized recipient of a face transplant. JCI Insight, 2017, 2, .	5.0	18
79	CTLA-4 Is Important in Maintaining Long-Term Survival of Cardiac Allografts. Transplantation, 2005, 79, 897-903.	1.0	17
80	Transitional Cell Carcinoma of the Native Urinary Tract After Kidney Transplantation: Recommendations Following a Long-Term Retrospective Analysis. American Journal of the Medical Sciences, 2011, 341, 478-483.	1.1	17
81	Hypophosphatemia in Kidney Transplant Recipients: Report of Acute Phosphate Nephropathy as a Complication of Therapy. American Journal of Kidney Diseases, 2011, 57, 641-645.	1.9	17
82	A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transplant International, 2007, 20, 505-511.	1.6	16
83	Regulatory T Cells Maintain Peripheral Tolerance to Islet Allografts Induced by Intrathymic Injection of MHC Class I Allopeptides. Cell Transplantation, 1999, 8, 375-381.	2.5	15
84	Donor-specific antibodies and antibody-mediated rejection in vascularized composite allotransplantation. Current Opinion in Organ Transplantation, 2016, 21, 510-515.	1.6	15
85	The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States. MDM Policy and Practice, 2018, 3, 238146831878181.	0.9	15
86	Immunologic monitoring in kidney transplant recipients. Kidney Research and Clinical Practice, 2013, 32, 52-61.	2.2	14
87	Beyond calcineurin inhibitors. Current Opinion in Nephrology and Hypertension, 2013, 22, 689-697.	2.0	14
88	Reduction in circulating level of HMGB-1 following continuous renal replacement therapy in sepsis. Cytokine, 2016, 83, 206-209.	3.2	14
89	The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death. Transplantation, 2017, 101, 2207-2212.	1.0	14
90	Regulatory Allospecific T Cell Clones Abrogate Chronic Allograft Rejection. Journal of the American Society of Nephrology: JASN, 2009, 20, 820-830.	6.1	13

#	Article	IF	CITATIONS
91	Causes and management of postrenal transplant diarrhea. Current Opinion in Nephrology and Hypertension, 2017, 26, 484-493.	2.0	13
92	Chronic Rejection: Insights from a Novel Immunosuppressive-Free Model of Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2004, 15, 687-694.	6.1	12
93	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2016, 35, 1295-1302.	0.6	12
94	Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients. PLoS ONE, 2017, 12, e0177339.	2.5	12
95	Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation. Frontiers in Immunology, 2021, 12, 618737.	4.8	12
96	Face Transplantation in a Highly Sensitized Recipient. Military Medicine, 2016, 181, 221-226.	0.8	11
97	New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transplant Infectious Disease, 2018, 20, e12985.	1.7	11
98	Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. American Journal of Transplantation, 2019, 19, 1518-1528.	4.7	11
99	Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. Journal of Clinical Investigation, 2021, 131, .	8.2	11
100	Stem Cell Therapy in Kidney Transplantation. JAMA - Journal of the American Medical Association, 2012, 308, 130.	7.4	10
101	Recombinant <scp>PTH</scp> therapy for severe hypoparathyroidism after kidney transplantation in preâ€transplant parathyroidectomized patients: review of the literature and a case report. Clinical Transplantation, 2015, 29, 951-957.	1.6	10
102	Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2497.	2.4	10
103	The Real World Impact of APOL1 Variants on Kidney Transplantation. Transplantation, 2016, 100, 16-17.	1.0	9
104	Novel Targets of Immunosuppression in Transplantation. Clinics in Laboratory Medicine, 2019, 39, 157-169.	1.4	9
105	High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury. Journal of Translational Medicine, 2020, 18 , 175 .	4.4	9
106	The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplantation Reviews, 2021, 35, 100649.	2.9	9
107	Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes. Kidney International, 2018, 93, 1227-1239.	5.2	8
108	Impact of Accidental Discovery of Renal Cell Carcinoma at Time of Renal Transplantation on Patient or Graft Survival. Transplantation, 2011, 92, 1123-1128.	1.0	7

#	Article	IF	Citations
109	Human leukocyte antigen matching in renal transplantation: an update. Current Opinion in Nephrology and Hypertension, 2000, 9, 683-687.	2.0	6
110	IL-6 production by monocytes is associated with graft function decline in patients with borderline changes suspicious for acute T-cell-mediated rejection: a pilot study. Transplant International, 2018, 31, 92-101.	1.6	6
111	Cell Therapy in Solid Organ Transplantation. Current Gene Therapy, 2019, 19, 71-80.	2.0	6
112	New Approaches For Desensitization Strategies Prior to Kidney Transplantation. American Journal of Kidney Diseases, 2009, 53, 370-372.	1.9	5
113	The Limits of Linked Suppression for Regulatory T Cells. Frontiers in Immunology, 2016, 7, 82.	4.8	5
114	Significance of biologics in renal transplantation. Current Opinion in Organ Transplantation, 2018, 23, 51-62.	1.6	5
115	Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?. Nature Clinical Practice Nephrology, 2006, 2, 134-135.	2.0	3
116	Imaging cell biology in transplantation. Transplant International, 2016, 29, 1349-1351.	1.6	3
117	Immunologic Risk Assessment and Approach to Immunosuppression Regimen in Kidney Transplantation. Clinics in Laboratory Medicine, 2019, 39, 643-656.	1.4	3
118	Posttransplantation Hypomagnesemia as a Predictor of Better Graft Function after Transplantation. Kidney and Blood Pressure Research, 2020, 45, 982-995.	2.0	3
119	Induction Therapy: Are We Picking Our Battles?. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 356-357.	4.5	2
120	Predictive biomarkers of renal allograft failure. Expert Opinion on Medical Diagnostics, 2008, 2, 1279-1290.	1.6	2
121	Combination Therapy With Plasmapheresis, IVIG, and Rituximab Provides Benefit in the Management of Early Antibody Mediated Rejection in Lung Transplant in a Pilot Cohort. Chest, 2013, 144, 1018A.	0.8	2
122	Human leukocyte antigen antibody sensitization, lung transplantation, and health equity. American Journal of Transplantation, 2022, 22, 698-704.	4.7	2
123	Potential Roles of Siglecs in the Regulation of Allo-Immune Reaction. Current Protein and Peptide Science, 2019, 20, 823-828.	1.4	2
124	Adenosinergic Pathway and Linked Suppression: Two Critical Suppressive Mechanisms of Human Donor Antigen Specific Regulatory T Cell Lines Expanded Post Transplant. Frontiers in Immunology, 2022, 13, 849939.	4.8	2
125	Presence of Anti-HLA Antibodies at High Threshold in Patients Listed for Lung Transplantation Is Associated With a Lower Transplant Rate and a Higher Antibody Mediated Rejection Incidence Posttransplant. Chest, 2013, 144, 1015A.	0.8	1
126	First Report of Perfluorobutane Microsphere–Enhanced Ultrasound in the Transplant Kidney. Transplantation, 2019, 103, e283-e284.	1.0	1

#	Article	IF	CITATIONS
127	Noninfectious Complications after Kidney Transplantation. , 2010, , 568-579.		0
128	A new molecular approach to the diagnosis of acute rejection. Nature Reviews Nephrology, 2013, 9, 631-632.	9.6	0
129	SP690LONG TERM OUTCOMES OF HIGHLY SENSITIZED KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2016, 31, i324-i325.	0.7	0
130	Developing a Rationale for an Appropriate Immunosuppressive Regimen in Lung vs Kidney Transplant Recipients. Transplantation, 2018, 102, S691.	1.0	0
131	The emerging role of the GPR109A (HCA2/PUMAâ€C) receptor in regulating macrophage function. FASEB Journal, 2013, 27, 649.4.	0.5	O
132	THE ROLE OF CTLA4 NEGATIVE SIGNALING PATHWAY IN THE INDUCTION OF ACQUIRED THYMIC TOLERANCE IN VIVO. Transplantation, 1998, 65, S168.	1.0	0
133	Transplantation Immunology. , 0, , 649-666.		O
134	Introduction: Moving Toward a More Personalized Approach to Kidney Transplantation. Seminars in Nephrology, 2022, 42, 1.	1.6	0